Peripheral Arterial Disease Clinical Trial
Official title:
Exercise Test and Sequential Training Strategies in Peripheral Arterial Disease
Verified date | May 2019 |
Source | Chang Gung Memorial Hospital |
Contact | n/a |
Is FDA regulated | No |
Health authority | |
Study type | Interventional |
Diabetic lower extremity disease, including peripheral vascular disease, peripheral
neuropathy, foot ulcers, or leg amputation. Among them, peripheral arterial disease (PAD) is
an important expression of systemic atherosclerosis. With the progress of the disease,
impaired peripheral blood circulation will lead to many symptoms and signs, such as pain,
paresthesia, and numbness.
In past studies show that regular exercise with moderate intensity may help to improve
metabolism and hemodynamic characteristics of the individual. In addition, many studies have
found that despite substantial organic changes in downstream tissue, exercise training can
improve walking ability and aerobic capacity in patients with peripheral arterial disease.
To enhance exercise capacity in patients with PAD may involve redistribution of blood flow
from vascular beds with lower O 2 exchange rates towards exercising ischemic muscles, an
increase in nutritive leg muscle blood flow at the expense of regional shunting mechanisms,
increased peripheral O 2 use during exercise attributable to more optimal distribution of leg
blood flow, and possible increased muscle capillary density and mitochondrial capacity.
Therefore, we tried to mimic local (leg) ischemic- reperfusion by systemic exercise, or to
practice remote preconditioning effect by interval occlusion of the blood vessel in the upper
arm which acquired ischemic preconditioning effect, and to improve local blood flow.
Furthermore, the hemagglutination performance in PAD patients may also be used as an
important indicator of cardiovascular disease.
Status | Recruiting |
Enrollment | 100 |
Est. completion date | December 31, 2019 |
Est. primary completion date | December 31, 2019 |
Accepts healthy volunteers | No |
Gender | All |
Age group | 20 Years to 80 Years |
Eligibility |
Inclusion Criteria: - Ankle-brachial index <0.9 Exclusion Criteria: - 1.<20 years old 2. There are other diseases or behavioral restrictions that prevent exercise training 3. Other exercise contraindications: 1. unstable angina 2. resting systolic blood pressure greater than 200 mmHg or diastolic blood pressure greater than 110 mmHg 3. orthostatic blood pressure drop greater than 20 mmHg with symptoms 4. Symptomatic severe aortic stenosis 5. Acute systemic infection, accompanied by fever, body aches, or swollen lymph glands 6. Uncontrolled cardiac dysrhythmias causing symptoms or hemodynamic compromise 7. Uncontrolled symptomatic heart failure 8. High-degree atrioventricular blocks 9. Acute myocarditis or pericarditis 10. Acute pulmonary embolus or pulmonary infarction 11. a recent significant change in the resting electrocardiogram suggesting significant ischemia, 12. recent myocardial infarction (within 2 d), or other acute cardiac events |
Country | Name | City | State |
---|---|---|---|
Taiwan | Department of Physical Medicine and Rehabilitation of Keelung Chang Gung Memorial hospital | Keelung |
Lead Sponsor | Collaborator |
---|---|
Chang Gung Memorial Hospital |
Taiwan,
Type | Measure | Description | Time frame | Safety issue |
---|---|---|---|---|
Primary | physical fitness (peak oxygen consumption) | oxygen consumption in cc/min/kg measured by Carefusion(TM) during cardiopulmonary exercise test | after 36 session exercise training, up to 12 weeks | |
Primary | physical fitness (exercise duration) | exercise duration in seconds measured during cardiopulmonary exercise test | after 36 session exercise training, up to 12 weeks | |
Primary | physical fitness (walking distance) | walking distance in meters measured during six minutes walking test | after 36 session exercise training, up to 12 weeks |
Status | Clinical Trial | Phase | |
---|---|---|---|
Recruiting |
NCT06032065 -
Sequential Multiple Assessment Randomized Trial of Exercise for PAD: SMART Exercise for PAD (SMART PAD)
|
Phase 3 | |
Active, not recruiting |
NCT03987061 -
MOTIV Bioresorbable Scaffold in BTK Artery Disease
|
N/A | |
Recruiting |
NCT03506633 -
Impacts of Mitochondrial-targeted Antioxidant on Peripheral Artery Disease Patients
|
N/A | |
Active, not recruiting |
NCT03506646 -
Dietary Nitrate Supplementation and Thermoregulation
|
N/A | |
Active, not recruiting |
NCT04677725 -
NEtwork to Control ATherothrombosis (NEAT Registry)
|
||
Recruiting |
NCT05961943 -
RESPONSE-2-PAD to Reduce Sedentary Time in Peripheral Arterial Disease Patients
|
N/A | |
Recruiting |
NCT06047002 -
Personalised Antiplatelet Therapy for Patients With Symptomatic Peripheral Arterial Disease
|
||
Completed |
NCT03185052 -
Feasibility of Outpatient Care After Manual Compression in Patients Treated for Peripheral Arterial Disease by Endovascular Technique With 5F Sheath Femoral Approach
|
N/A | |
Recruiting |
NCT05992896 -
A Study of Loco-Regional Liposomal Bupivacaine Injection
|
Phase 4 | |
Completed |
NCT04635501 -
AbsorbaSeal (ABS 5.6.7) Vascular Closure Device Trial
|
N/A | |
Recruiting |
NCT04584632 -
The Efemoral Vascular Scaffold System (EVSS) for the Treatment of Patients With Symptomatic Peripheral Vascular Disease From Stenosis or Occlusion of the Femoropopliteal Artery
|
N/A | |
Withdrawn |
NCT03994185 -
The Merit WRAPSODY™ Endovascular Stent Graft for Treatment of Iliac Artery Occlusive Disease
|
N/A | |
Withdrawn |
NCT03538392 -
Serranator® Alto Post Market Clinical Follow Up (PMCF) Study
|
||
Recruiting |
NCT02915796 -
Autologous CD133(+) Cells as an Adjuvant to Below the Knee Percutaneous Transluminal Angioplasty
|
Phase 1 | |
Active, not recruiting |
NCT02900924 -
Observational Study to Evaluate the BioMimics 3D Stent System: MIMICS-3D
|
||
Completed |
NCT02901847 -
To Evaluate the Introduction of a Public Health Approach to Peripheral Arterial Disease (PAD) Using National Centre for Sport and Exercise Medicine Facilities.
|
N/A | |
Not yet recruiting |
NCT02455726 -
Magnesium Oral Supplementation to Reduce Pain Inpatients With Severe Peripheral Arterial Occlusive Disease
|
N/A | |
Not yet recruiting |
NCT02387450 -
Reduced Cardiovascular Morbi-mortality by Sildenafil in Patients With Arterial Claudication
|
Phase 2/Phase 3 | |
Withdrawn |
NCT02126540 -
Trial of Pantheris System, an Atherectomy Device That Provides Imaging While Removing Plaque in Lower Extremity Arteries
|
N/A | |
Completed |
NCT02384980 -
Saving Life and Limb: FES for the Elderly With PAD
|
Phase 1 |